Klotho Neurosciences, Inc. (KLTO) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Omaha, NE, アメリカ. 現CEOは Joseph A. Sinkule.
KLTO を有する IPO日 2022-04-29, 3 名の正社員, に上場 NASDAQ Global Market, 時価総額 $20.08M.
Klotho Neurosciences, Inc., a biopharmaceutical company, develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders. Its lead gene therapy product candidates include AMI-101 for the treatment or prevention of Alzheimer's disease; and AMI-202 to treat and prevent amyotrophic lateral sclerosis. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. The company is based in Omaha, Nebraska.
